These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12427292)

  • 1. Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study.
    Walkup J; Labellarte M; Riddle MA; Pine DS; Greenhill L; Fairbanks J; Klein R; Davies M; Sweeney M; Abikoff H; Hack S; Klee B; Bergman RL; Lynn D; McCracken J; March J; Gammon P; Vitiello B; Ritz L; Roper M;
    J Child Adolesc Psychopharmacol; 2002; 12(3):175-88. PubMed ID: 12427292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial.
    Stein DJ; Westenberg HG; Yang H; Li D; Barbato LM
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):317-23. PubMed ID: 14604447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
    Tollefson GD; Birkett M; Koran L; Genduso L
    J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep-related problems among children and adolescents with anxiety disorders.
    Alfano CA; Ginsburg GS; Kingery JN
    J Am Acad Child Adolesc Psychiatry; 2007 Feb; 46(2):224-32. PubMed ID: 17242626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group.
    N Engl J Med; 2001 Apr; 344(17):1279-85. PubMed ID: 11323729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoxetine for childhood anxiety disorders.
    Birmaher B; Waterman GS; Ryan N; Cully M; Balach L; Ingram J; Brodsky M
    J Am Acad Child Adolesc Psychiatry; 1994 Sep; 33(7):993-9. PubMed ID: 7961355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents.
    Fairbanks JM; Pine DS; Tancer NK; Dummit ES; Kentgen LM; Martin J; Asche BK; Klein RG
    J Child Adolesc Psychopharmacol; 1997; 7(1):17-29. PubMed ID: 9192539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open trial of fluvoxamine for hypochondriasis.
    Fallon BA; Qureshi AI; Schneier FR; Sanchez-Lacay A; Vermes D; Feinstein R; Connelly J; Liebowitz MR
    Psychosomatics; 2003; 44(4):298-303. PubMed ID: 12832595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.
    Reinblatt SP; DosReis S; Walkup JT; Riddle MA
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):119-26. PubMed ID: 19364290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study.
    Black B; Uhde TW
    J Am Acad Child Adolesc Psychiatry; 1994 Sep; 33(7):1000-6. PubMed ID: 7961338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
    Houck C
    Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study.
    Dannon PN; Lowengrub K; Musin E; Gonopolsky Y; Kotler M
    J Clin Psychopharmacol; 2007 Dec; 27(6):620-4. PubMed ID: 18004130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open trial of fluoxetine in the treatment of panic attacks.
    Gorman JM; Liebowitz MR; Fyer AJ; Goetz D; Campeas RB; Fyer MR; Davies SO; Klein DF
    J Clin Psychopharmacol; 1987 Oct; 7(5):329-32. PubMed ID: 3500189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on fluvoxamine in anxiety disorders in children and adolescents.
    Cheer SM; Figgitt DP
    CNS Drugs; 2002; 16(2):139-44. PubMed ID: 11825104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial.
    Clark DB; Birmaher B; Axelson D; Monk K; Kalas C; Ehmann M; Bridge J; Wood DS; Muthen B; Brent D
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1263-70. PubMed ID: 16292118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder.
    Koran LM; Bromberg D; Hornfeldt CS; Shepski JC; Wang S; Hollander E
    Compr Psychiatry; 2010; 51(4):373-9. PubMed ID: 20579510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fluoxetine versus fluvoxamine for treatment of chronic pain].
    Ciaramella A; Grosso S; Poli P
    Minerva Anestesiol; 2000; 66(1-2):55-61. PubMed ID: 10736983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
    Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoxetine in the treatment of anger: an open clinical trial.
    Rubey RN; Johnson MR; Emmanuel N; Lydiard RB
    J Clin Psychiatry; 1996 Sep; 57(9):398-401. PubMed ID: 9746447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.